Navigation Links
OHSU Cancer Instutute researchers find abnormalities in gene for melanoma
Date:5/29/2008

PORTLAND, Ore. New research from the Oregon Health & Science University Cancer Institute about mutations in melanoma may bring a wellspring of hope to many patients.

Researchers have discovered that there are several different kinds of DNA abnormalities that can occur in a gene called the KIT gene. These abnormalities are associated with different kinds of acral and mucosal melanomas, which are less common, but highly malignant forms of skin cancer. Acral melanomas are found on the palms of hands, the soles of feet and under nails. Mucosal melanomas are found in the mucous membranes of some organs of the body.

If scientists can figure out the mutation, effective treatments can follow, explained Michael Heinrich, M.D., co-principal investigator, OHSU Cancer Institute member and head of the Hematology and Medical Oncology Section at the Portland Veterans Affairs Medical Center. The co-investigator is Christopher Corless, M.D., Ph.D., OHSU Cancer Institute member.

The research will be presented Sunday, June 1, at 5 p.m. during the annual American Society of Clinical Oncology in Chicago.

This study builds on recent research about the first instance in which a womans metastatic melanoma was driven into remission by the targeted therapy drug, Gleevec, which was developed at the OHSU Cancer Institute. Previously there had been few effective treatments for melanoma patients with metastatic disease. But not all melanomas respond so successfully to Gleevec.

In the current study, Heinrich and colleagues studied 129 samples gathered from people with different types of melanoma and found that there is a high rate of mutations in these cancers.

This means that if we can find the melanoma early, it can be screened to see what type of mutations are present, and eventually you can get the right medication or treatment, Heinrich said.

Heinrich explained that it is similar to testing of breast cancer tumors to decide if patients should receive specific treatments such as hormonal inhibitors and/or the drug Herceptin. He predicts that drugs to treat the mutations found in melanomas could be developed in as little as 18 months.

In the very near future, we can do DNA testing of melanomas to better know exactly what is driving the growth of the cancer and select the best treatment. When we know what is wrong, we can do something to fix it, Heinrich said.

The same KIT mutations as those found in gastrointestinal stromal tumors (GIST) are present in mucosal and acral melanomas. Gleevecs effectiveness against tumors with KIT mutations was first demonstrated by Heinrich. Recent studies have found KIT mutations in 11 percent of acral melanomas 21 percent of mucosal melanomas and 17 percent of melanomas arising in sun-damaged skin.

Melanoma is found predominantly in skin but also in the bowel and the eye. It is the most serious type of cancer of the skin. Each year in the United States, more than 53,600 people learn they have melanoma and the percentage of people who develop melanoma has more than doubled in the past 30 years, according to the National Cancer Institute.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Enzyme may hold key to improved targeting of cancer-fighting drugs
2. Diabetes doubles liver cancer risk for patients with advanced hepatitis C
3. OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy
4. Certain Tests in ERs Raise Cancer Risk for Some
5. Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
6. Initiative Links Celebrities to Cancer Research
7. USC researchers identify genetic markers that predict efficacy of novel cancer drug
8. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
9. Susan G. Komen for the Cure(R) Celebrity Ambassadors to Convene in Nations Capital to Help Race for the Cure, End Breast Cancer Forever
10. American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients
11. USC study finds sex, age and ethnicity assciated with colorectal cancer survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of ... for this weekend’s Big Game. Take the stress out of your party preparation – ... guests happy at every stage of the game. , “The key to hosting a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , February 5, 2016 Site ... Today, VoicePower Ltd - The Speech Recognition People, announced their latest ... to improve patient care, reduce turnaround times and to save the ... ,- VoicePower client since 2013 Challenge: --> ... --> - Six doctors ,- Wirral CCG ,- VoicePower ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... for structural heart disease and critical care monitoring, announced ... repurchase (ASR) agreement with Morgan Stanley & Co. LLC ... repurchase is part of the Company,s previously authorized program ... common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology: